Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹7,215 Cr
verified against source
Revenue YoY
7%
reported change
EBITDA
₹2,111 Cr
latest reported figure
Source
nse xbrl
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Dr. Reddy's delivered a solid Q3 FY24 with INR 7,215 crore revenue (+7% YoY) and INR 1,379 crore PAT (+11% YoY), driven by US generics (up 7% to $401M) and Europe (up 8% to EUR 55M). EBITDA margin held at 29.3% despite SG&A investments. Management highlighted a pipeline of 26 meaningful US launches over FY25-26 and six biosimilars targeting first-to-market by FY30. India base business is expected to return to double-digit growth from FY25, supported by key brands growing 1.5x market. Risks include potential OAI outcome at FTO-3 facility (10 observations) and price erosion in US generics, though management noted stable pricing trends.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects India base business to return to double-digit growth in coming quarters, driven by key brands growing at 1.5x market rate.
- Approximately 26 products with potential sales >$10M each are expected to launch in the US over the next two years, subject to approvals.
- Biosimilar pipeline includes six products aiming for first-to-market status, with first launch expected in early CY2027.
- SG&A spend will remain higher in absolute terms as investments in brands and pipeline products continue, with revenue growth expected to provide operating leverage.
Risks flagged
- FDA issued Form 483 with 10 observations at FTO-3; management has responded but risk of OAI classification could impact approvals and reputation.
- Price erosion in US generics continues, though management describes it as stable. Any acceleration could pressure margins.
- Revlimid contribution remains meaningful; any unexpected decline could impact cash generation and ability to invest in pipeline.
- Geopolitical tensions are causing sea route disruptions; management is building inventory but costs could rise if situation persists.
Key quotes
- We are not in a shopping spree. Buying that we believe is good for us and strategically.
- We are trying to be positioned as a partner for customers and certain areas like that.
- Most of the growth that we have, you know, this product is more longer term nature rather than one time buy.
Research modules